Search Results - "Romeo, Margarita"

Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial by Coleman, Robert L, Lorusso, Domenica, Oaknin, Ana, Cecere, Sabrina Chiara, Denys, Hannelore, Colombo, Nicoletta, van Gorp, Toon, Konner, Jason A, Romeo Marin, Margarita, Harter, Philipp, Murphy, Conleth, Wang, Yuemei, Esteves, Brooke, Method, Michael, Matulonis, Ursula

“…The single-arm, phase II SORAYA trial (NCT04296890) of mirvetuximab soravtansine-gynx in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer…”
Get more information

Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial by Pignata, Sandro, Oza, Amit, Hall, Geoff, Pardo, Beatriz, Madry, Radoslaw, Cibula, David, Klat, Jaroslav, Montes, Ana, Glasspool, Rosalind, Colombo, Nicoletta, Pete, Imre, Herrero Ibáñez, Ana, Marín, Margarita Romeo, Ilieva, Rumyana, Timcheva, Constanta, Di Maio, Massimo, Blakeley, Christopher, Taylor, Rosie, Barnicle, Alan, Clamp, Andrew

“…The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with…”
Get full text

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer by Leary, Alexandra, Estévez-García, Purificación, Sabatier, Renaud, Ray-Coquard, Isabelle, Romeo, Margarita, Barretina-Ginesta, Pilar, Gil-Martin, Marta, Garralda, Elena, Bosch-Barrera, Joaquim, Morán, Teresa, Martin-Martorell, Paloma, Nadal, Ernest, Gascón, Pere, Rodon, Jordi, Lizcano, Jose M, Muñoz-Guardiola, Pau, Fierro-Durán, Gemma, Pedrós-Gámez, Oriol, Pérez-Montoyo, Héctor, Yeste-Velasco, Marc, Cortal, Marc, Pérez-Campos, Antonio, Alfon, Jose, Domenech, Carles, Pérez-Fidalgo, Alejandro, Oaknin, Ana

“…Carboplatin and paclitaxel (CP) have been the standard of care for advanced/recurrent endometrial cancer (EC) for many years. However, this chemotherapy…”
Get full text

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors by Felip, Eudald, Pradenas, Edwards, Romeo, Margarita, Marfil, Silvia, Trinité, Benjamin, Urrea, Víctor, Hernández, Ainhoa, Ballana, Ester, Cucurull, Marc, Mateu, Lourdes, Massanella, Marta, Clotet, Bonaventura, Morán, Teresa, Blanco, Julià

“…Patients with solid tumors have been a risk group since the beginning of the SARS‐CoV‐2 pandemic due to more significant complications, hospitalizations or…”
Get full text

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer by Leary, Alexandra, Estévez-García, Purificación, Sabatier, Renaud, Ray-Coquard, Isabelle, Romeo, Margarita, Barretina-Ginesta, Pilar, Gil-Martin, Marta, Garralda, Elena, Bosch-Barrera, Joaquim, Morán, Teresa, Martin-Martorell, Paloma, Nadal, Ernest, Gascón, Pere, Rodon, Jordi, Lizcano, Jose M, Muéoz-Guardiola, Pau, Fierro-Durán, Gemma, Pedrós-Gámez, Oriol, Pérez-Montoyo, Héctor, Yeste-Velasco, Marc, Cortal, Marc, Pérez-Campos, Antonio, Alfon, Jose, Domenech, Carles, Pérez-Fidalgo, Alejandro, Oaknin, Ana

Get full text

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery by Plaja, Andrea, Teruel, Iris, Ochoa-de-Olza, Maria, Cucurull, Marc, Arroyo, Álvaro Javier, Pardo, Beatriz, Ortiz, Irene, Gil-Martin, Marta, Piulats, Josep María, Pla, Helena, Fina, Claudia, Carbó, Anna, Barretina-Ginesta, Maria-Pilar, Martínez-Román, Sergio, Carballas, Elvira, González, Andrea, Esteve, Anna, Romeo, Margarita

“…Despite a multimodal radical treatment, mortality of advanced epithelial ovarian cancer (AEOC) remains high. Host-related factors, such as systemic…”
Get full text

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis by Gutiérrez-Chamorro, Lucía, Felip, Eudald, Bernat-Peguera, Adrià, Ezeonwumelu, Ifeanyi Jude, Teruel, Iris, Martínez-Cardús, Anna, Clotet, Bonaventura, Riveira-Muñoz, Eva, Romeo, Margarita, Margelí, Mireia, Ballana, Ester

“…SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase which has been proposed as a putative prognostic factor in haematological cancers and…”
Get full text

Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor by Romeo, Margarita, Pons, Francesc, Barretina, Pilar, Radua, Joaquim

“…Borderline ovarian tumors (BOTs) are a subset of epithelial ovarian tumors with low malignant potential but significant risk of relapse (10% to 30%)…”
Get full text

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer by Romeo, Margarita, Pardo, Juan Carlos, Martínez-Cardús, Anna, Martínez-Balibrea, Eva, Quiroga, Vanesa, Martínez-Román, Sergio, Solé, Francesc, Margelí, Mireia, Mesía, Ricard

“…Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ovarian carcinomas (HGSOC). Deficient HR (DHR) constitutes…”
Get full text

Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer by Pous, Anna, Bernat-Peguera, Adrià, López-Paradís, Assumpció, Cirauqui, Beatriz, Quiroga, Vanesa, Teruel, Iris, Felip, Eudald, Ferrando-Díez, Angelica, Bergamino, Milana, Boronat, Laia, Romeo, Margarita, Soler, Gemma, Mariño, Christian, Rodríguez-Martínez, Paula, Pons, Laura, Ballana, Ester, Martinez-Cardús, Anna, Margelí, Mireia

“…Human epidermal growth factor receptor 2 (HER2)-low has emerged as a potential new entity in breast cancer (BC). Data on this subset are limited, and…”
Get full text

Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial by Chase, Dana M., Marín, Margarita Romeo, Backes, Floor, Han, Sileny, Graybill, Whitney, Mirza, Mansoor Raza, Pothuri, Bhavana, Mangili, Giorgia, O'Malley, David M., Berton, Dominique, Willmott, Lyndsay, Baumann, Klaus, Coleman, Robert L., Safra, Tamar, Heinzelmann-Schwarz, Viola, Lorusso, Domenica, Karl, Florian M., Woodward, Tatia, Monk, Bradley J., Gonzalez-Martin, Antonio

“…Progression-free survival (PFS) is an important early efficacy endpoint in ovarian cancer (OC) and its relevance to patients should be assessed. PRIMA, a phase…”
Get full text

Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup by Creutzberg, Carien L, Kim, Jae-Weon, Eminowicz, Gemma, Allanson, Emma, Eberst, Lauriane, Kim, Se Ik, Nout, Remi A, Park, Jeong-Yeol, Lorusso, Domenica, Mileshkin, Linda, Ottevanger, Petronella B, Brand, Alison, Mezzanzanica, Delia, Oza, Amit, Gebski, Val, Pothuri, Bhavana, Batley, Tania, Gordon, Carol, Mitra, Tina, White, Helen, Howitt, Brooke, Matias-Guiu, Xavier, Ray-Coquard, Isabelle, Gaffney, David, Small, William, Miller, Austin, Concin, Nicole, Powell, Matthew A, Stuart, Gavin, Bookman, Michael A, Barretina-Ginesta, Pilar, Bennett, Katherine, Berek, Jonathan, Berger, Regina, Bjørge, Line, Boere, Ingrid, Brennan, Donal, Bruchim, Ilan, Chang, Ting-Chang, Chavez Blanco, Adriana, Chen, Xiaojun, Colombo, Nicoletta, Crosbie, Emma, Denys, Hannelore, Duska, Linda, Fruehauf, Filip, Gomez Garcia, Eva Maria, van Gorp, Toon, Grimm, Christoph, Guitmann, Gustavo, Han, Kathy, Hanker, Lars, Harano, Kenichi, Hasegawa, Kosei, Herrington, C Simon, Ip, Philip, Joly, Florence, Khaw, Pearly, Kohn, Elise, Kristeleit, Rebecca, Kroep, Judith, Leary, Alexandra, Lee, Jung-Yun, Lheureux, Stephanie, Liu, Jihong, Mackay, Helen, Mahner, Sven, Mariani, Andrea, McAlpine, Jessica, Mikami, Yoshiki, Mirza, Mansoor Raza, Mukhopadhyay, Asima, Nagao, Shoji, Ng, Joseph, Nogueira-Rodrigues, Angelica, Novák, Zoltán, O'Donnell, Jennifer, Osborne, Sherill, Perez-Fidalgo, J. Alejandro, Romeo Marin, Margarita, Roy Chowdhury, Rahul, Sadozye, Azmat, Safra, Tamar, Scott, Claire, Sehouli, Jalid, Slomovitz, Brian, Tan, David, Taylor, Alexandra, Valabrega, Giorgio, Veneziani, Ana, Verhoeven, Karen, Vetter, Marcus, Wampfler, Julian, Westin, Shannon, Wimberger, Pauline, Zola, Paolo

“…The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2–3, 2023…”
Get full text

354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study by Makker, Vicky, Aghajanian, Carol, Cohn, Allen, Romeo, Margarita, Bratos, Raquel, Brose, Marcia, Messing, Mark, Dutta, Lea, Dutcus, Corina, Huang, Jie, Schmidt, Emmett, Orlowski, Robert, Taylor, Matthew

“…BackgroundLenvatinib is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT. Pembrolizumab is an anti-programmed death-1 monoclonal antibody…”
Get full text

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer by Garcia Garcia, Yolanda, de Juan Ferré, Ana, Mendiola, Cesar, Barretina-Ginesta, Maria-Pilar, Gaba Garcia, Lydia, Santaballa Bertrán, Ana, Bover Barcelo, Isabel, Gil-Martin, Marta, Manzano, Aranzazu, Rubio Pérez, Maria Jesús, Romeo Marin, Margarita, Arqueros Núñez, Cristina, García-Martínez, Elena, Gonzalez Martin, Antonio

“…Bevacizumab is an approved treatment after primary debulking surgery for ovarian cancer. However, there is limited information on bevacizumab added to…”
Get more information

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer by Makker, Vicky, Taylor, Matthew H, Aghajanian, Carol, Oaknin, Ana, Mier, James, Cohn, Allen L, Romeo, Margarita, Bratos, Raquel, Brose, Marcia S, DiSimone, Christopher, Messing, Mark, Stepan, Daniel E, Dutcus, Corina E, Wu, Jane, Schmidt, Emmett V, Orlowski, Robert, Sachdev, Pallavi, Shumaker, Robert, Casado Herraez, Antonio

“…Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with…”
Get full text

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study by Matulonis, Ursula A, Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A, Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G, Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L

“…Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab…”
Get full text

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells by Muñoz-Guardiola, Pau, Casas, Josefina, Megías-Roda, Elisabet, Solé, Sònia, Perez-Montoyo, Héctor, Yeste-Velasco, Marc, Erazo, Tatiana, Diéguez-Martínez, Nora, Espinosa-Gil, Sergio, Muñoz-Pinedo, Cristina, Yoldi, Guillermo, Abad, Jose L, Segura, Miguel F, Moran, Teresa, Romeo, Margarita, Bosch-Barrera, Joaquim, Oaknin, Ana, Alfón, Jose, Domènech, Carles, Fabriàs, Gemma, Velasco, Guillermo, Lizcano, Jose M

“…ABTL0812 is a first-in-class small molecule with anti-cancer activity, which is currently in clinical evaluation in a phase 2 trial in patients with advanced…”
Get full text

Abstract LB112: SAMHD1: A new Prognostic Marker in Breast Cancer (BC) by Margeli, Mireia, Felip, Eudald, Chamorro, Lucia Gutierrez, Riveira, Eva, Layos, Laura, Moran, Teresa, Romeo, Margarita, Matinez-Cardús, Anna, Ballana, Ester

“…Abstract Introduction SAMHD1 is a triphosphohydrolase that catalyzes the degradation of deoxynucleoside triphosphates (dNTP), and its function is tightly…”
Get full text

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update by Makker, Vicky, Aghajanian, Carol, Cohn, Allen L, Romeo, Margarita, Bratos, Raquel, Brose, Marcia S, Messing, Mark, Dutta, Lea, Dutcus, Corina E, Huang, Jie, Schmidt, Emmett V, Orlowski, Robert, Taylor, Matthew H

“…JCO The open-label phase Ib/II Study 111/KEYNOTE-146 of daily lenvatinib 20 mg plus pembrolizumab 200 mg once every 3 weeks showed promising efficacy and…”
Get full text

SER-ONCOVID: Seroconversion in solid-tumor cancer patients after COVID-19 diagnosis by Pous, Anna, Felip, Eudald, Etxaniz, Olatz, Hernandez Gonzalez, Ainhoa, España, Sofia, Romeo, Margarita, Pinato, David James, Esteve, Anna, Mesia, Ricard

“…Abstract only 2544 Background: Cancer patients (pts) represent a high-risk population for severe COVID-19. Cancer-associated immunosuppression may hinder in…”
Get full text